139 related articles for article (PubMed ID: 38534924)
1. Modeling 5-FU-Induced Chemotherapy Selection of a Drug-Resistant Cancer Stem Cell Subpopulation.
Ramović Hamzagić A; Cvetković D; Gazdić Janković M; Milivojević Dimitrijević N; Nikolić D; Živanović M; Kastratović N; Petrović I; Nikolić S; Jovanović M; Šeklić D; Filipović N; Ljujić B
Curr Oncol; 2024 Feb; 31(3):1221-1234. PubMed ID: 38534924
[TBL] [Abstract][Full Text] [Related]
2. CD44 and CD24 cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549.
Roudi R; Madjd Z; Ebrahimi M; Samani FS; Samadikuchaksaraei A
Cell Mol Biol Lett; 2014 Mar; 19(1):23-36. PubMed ID: 24363164
[TBL] [Abstract][Full Text] [Related]
3. Elevation in 5-FU-induced apoptosis in head and neck cancer stem cells by a combination of CDHP and GSK3β inhibitors.
Shigeishi H; Biddle A; Gammon L; Rodini CO; Yamasaki M; Seino S; Sugiyama M; Takechi M; Mackenzie IC
J Oral Pathol Med; 2015 Mar; 44(3):201-7. PubMed ID: 25169655
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer stem cells expressing different stem cell markers exhibit distinct biological characteristics.
Shao J; Fan W; Ma B; Wu Y
Mol Med Rep; 2016 Dec; 14(6):4991-4998. PubMed ID: 27840965
[TBL] [Abstract][Full Text] [Related]
5. CD133+, CD166+CD44+, and CD24+CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell lines.
Muraro MG; Mele V; Däster S; Han J; Heberer M; Cesare Spagnoli G; Iezzi G
Stem Cells Transl Med; 2012 Aug; 1(8):592-603. PubMed ID: 23197865
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer stem cells and intrinsic subtypes: controversies rage on.
Nakshatri H; Srour EF; Badve S
Curr Stem Cell Res Ther; 2009 Jan; 4(1):50-60. PubMed ID: 19149630
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer.
Wang C; Xie J; Guo J; Manning HC; Gore JC; Guo N
Oncol Rep; 2012 Oct; 28(4):1301-8. PubMed ID: 22895640
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
[TBL] [Abstract][Full Text] [Related]
9. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability.
Croker AK; Goodale D; Chu J; Postenka C; Hedley BD; Hess DA; Allan AL
J Cell Mol Med; 2009 Aug; 13(8B):2236-2252. PubMed ID: 18681906
[TBL] [Abstract][Full Text] [Related]
10. Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis.
Niess H; Camaj P; Renner A; Ischenko I; Zhao Y; Krebs S; Mysliwietz J; Jäckel C; Nelson PJ; Blum H; Jauch KW; Ellwart JW; Bruns CJ
Target Oncol; 2015 Jun; 10(2):215-27. PubMed ID: 24950733
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of stem cell markers by P21-activated kinase 1 contributes to 5-fluorouracil resistance of colorectal cancer.
Huynh N; Shulkes A; Baldwin G; He H
Cancer Biol Ther; 2016 Aug; 17(8):813-23. PubMed ID: 27260988
[TBL] [Abstract][Full Text] [Related]
12. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
[TBL] [Abstract][Full Text] [Related]
13. Machine Learning Model for Prediction of Development of Cancer Stem Cell Subpopulation in Tumurs Subjected to Polystyrene Nanoparticles.
Ramović Hamzagić A; Gazdić Janković M; Cvetković D; Nikolić D; Nikolić S; Milivojević Dimitrijević N; Kastratović N; Živanović M; Miletić Kovačević M; Ljujić B
Toxics; 2024 May; 12(5):. PubMed ID: 38787133
[TBL] [Abstract][Full Text] [Related]
14. A subpopulation of CD24⁺ cells in colon cancer cell lines possess stem cell characteristics.
Ke J; Wu X; Wu X; He X; Lian L; Zou Y; He X; Wang H; Luo Y; Wang L; Lan P
Neoplasma; 2012; 59(3):282-8. PubMed ID: 22329848
[TBL] [Abstract][Full Text] [Related]
15. Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation.
Louie E; Nik S; Chen JS; Schmidt M; Song B; Pacson C; Chen XF; Park S; Ju J; Chen EI
Breast Cancer Res; 2010; 12(6):R94. PubMed ID: 21067584
[TBL] [Abstract][Full Text] [Related]
16. Aldehyde dehydrogenase 1 identifies cells with cancer stem cell-like properties in a human renal cell carcinoma cell line.
Ueda K; Ogasawara S; Akiba J; Nakayama M; Todoroki K; Ueda K; Sanada S; Suekane S; Noguchi M; Matsuoka K; Yano H
PLoS One; 2013; 8(10):e75463. PubMed ID: 24116047
[TBL] [Abstract][Full Text] [Related]
17. Characterization of cancer stem cell drug resistance in the human colorectal cancer cell lines HCT116 and SW480.
Butler SJ; Richardson L; Farias N; Morrison J; Coomber BL
Biochem Biophys Res Commun; 2017 Aug; 490(1):29-35. PubMed ID: 28576498
[TBL] [Abstract][Full Text] [Related]
18. ABCG2 is a potential marker of tumor-initiating cells in breast cancer.
Sicchieri RD; da Silveira WA; Mandarano LR; de Oliveira TM; Carrara HH; Muglia VF; de Andrade JM; Tiezzi DG
Tumour Biol; 2015 Dec; 36(12):9233-43. PubMed ID: 26091795
[TBL] [Abstract][Full Text] [Related]
19. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer.
Lee HE; Kim JH; Kim YJ; Choi SY; Kim SW; Kang E; Chung IY; Kim IA; Kim EJ; Choi Y; Ryu HS; Park SY
Br J Cancer; 2011 May; 104(11):1730-8. PubMed ID: 21559013
[TBL] [Abstract][Full Text] [Related]
20. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
Cufi S; Corominas-Faja B; Vazquez-Martin A; Oliveras-Ferraros C; Dorca J; Bosch-Barrera J; Martin-Castillo B; Menendez JA
Oncotarget; 2012 Apr; 3(4):395-8. PubMed ID: 22565037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
